CRINETICS PHARM (CRNX)
(Delayed Data from NSDQ)
$29.24 USD
+1.02 (3.61%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $29.22 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRNX 29.24 +1.02(3.61%)
Will CRNX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRNX
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?
CRNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
Other News for CRNX
CRNX March 2026 Options Begin Trading
JonesTrading Remains a Buy on Crinetics Pharmaceuticals (CRNX)
Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly
CRNX to Highlight PALSONIFY Data at ENDO 2025 | CRNX Stock News
Crinetics announces new data from its program evaluating PALSONIFY